SEC Company Response from Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — May 7, 2008
Altimmune, Inc. (ALT) (CIK 0001326190)
Date: May 7, 2008 · CIK: 0001326190 · Accession: 0001104659-08-030861
AI Filing Summary & Sentiment
File numbers found in text: 001-32587
Referenced dates: May 2, 2008, May 2, 2008
Show Raw Text
CORRESP
1
filename1.htm
Michele Vaillant
Partner
T.
973.639.2011
F.
973.297.3826
mvaillant@mccarter.com
McCarter &
English, LLP
Four
Gateway Center
100
Mulberry Street
Newark,
NJ 07102
T.
973.622.4444
F.
973.624.7070
www.mccarter.com
May 7, 2008
VIA EDGAR
United States Securities and Exchange Commission
Office of Emerging Growth Companies
100 F Street, NE - Mail Stop 6010
Washington, D.C. 20549
Attn: Mr. Jeffrey Riedler
Ms. Sonia Barros
Re:
PharmAthene, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed on April 29, 2008
File No. 001-32587
Dear Sir and Madam:
On behalf of PharmAthene, Inc. (the “Company”), we hereby submit
the Company’s response to the Staff’s comment contained in the letter, dated May 2,
2008, from Jeffrey Riedler. For
convenience, the comment is set forth below followed by the Company’s response.
Proxy Card
1. Please provide for a mechanism enabling a
noteholder to vote for some nominees for director and vote against other
nominees for director. See Rule 14a-4(b)(2).
The Noteholder Proxy Card has
been revised to provide a mechanism enabling a Noteholder to vote for some
nominees for director and vote against other nominees for director in
accordance with Rule 14a-4(b)(2). A
clean and a marked version of the revised Noteholder Proxy Card are provided
together with this letter for consideration.
The Company’s representation letter is also provided.
Please contact the undersigned at 973-639-2011 to discuss any further
comments in this regard. Thank you.
Very truly
yours.
/s/ Michele
F. Vaillant
Michele F.
Vaillant
cc: David P. Wright, President
and
CEO
PHARMATHENE, INC.
ANNUAL
MEETING OF STOCKHOLDERS
Friday, June 13,
2008
10:00 a.m. New York Time
THE BEAR
STEARNS COMPANIES, INC.
383 Madison Avenue
New York,
NY 10179
8% Convertible Notes issued August 3, 2007
PharmAthene, Inc.
One Park Place, Suite 450
Annapolis, MD 21401
proxy
For The
Annual Meeting To Be Held June 13, 2008
The undersigned hereby constitutes and appoints John
Pappajohn and David P. Wright, and each of them, attorneys and agents, with
full power of substitution, to vote as proxy all 8% Convertible Notes issued August 3,
2007 of PharmAthene, Inc.(the “Company”) standing in the name of the
undersigned at the Annual Meeting of Stockholders of the Company to be held at
the offices of The Bear Stearns Companies, Inc. located at 383 Madison
Avenue, New York, New York 10179 at 10:00 a.m., New York time, on Friday, June 13,
2008, and at any adjournment or postponement thereof, in accordance with the
instructions noted below, and with discretionary authority with respect to such
other matters as may properly come before such meeting or any adjournment or
postponement thereof. Receipt of notice of such meeting and the Proxy Statement
therefor dated May , 2008 is hereby acknowledged.
This Proxy will be voted in
accordance with the Noteholder’s specifications hereon. In the absence of any
such specification, this Proxy will be voted:
·
“FOR” James H. Cavanaugh, Ph.D.,
Elizabeth Czerepak and Steven St. Peter as Directors of the Company.
The undersigned hereby revokes any
proxies heretofore given and directs said attorneys to act or vote as follows:
1. Election of directors:
01
James H. Cavanaugh, Ph.D.
02
Elizabeth Czerepak
o
Vote
FOR all
nominees
o
Vote
WITHHOLD
AUTHORITY to vote
03
Steven St. Peter
listed
(except as marked)
for all nominees
listed
FOR all nominees listed, except
that authority to vote withheld for the following nominee(s): Write the
number(s) of the nominee(s) in the box provided to the right.
1. Proposal to elect James H. Cavanaugh,
Ph.D., Elizabeth Czerepak and Steven St. Peter to the Board of Directors of the Company.
o
For
o
Against
THIS PROXY IS SOLICITED ON BEHALF
OF THE HOLDERS OF THE COMPANY’S 8% CONVERTIBLE NOTES ISSUED AUGUST 3, 2007
SIGN HERE EXACTLY AS NAME(S) APPEAR(S) ON
THE CARD
Date
Signature(s)
NOTE: When shares are held by joint tenants, both should sign. When
signing as attorney, trustee, administrator, executor, guardian, etc., please
indicate your full title as such. If a corporation, please sign in full
corporate name by President or other authorized officer. If a partnership,
please sign in full partnership name by authorized person.
Please complete and date this proxy and return it
promptly
in the enclosed postage-prepaid envelope.
PHARMATHENE,
INC.
ANNUAL
MEETING OF STOCKHOLDERS
Friday, June 13,
2008
10:00 a.m.
New York Time
THE BEAR
STEARNS COMPANIES, INC.
383 Madison
Avenue
New York,
NY 10179
8% Convertible Notes issued August 3, 2007
PharmAthene, Inc.
One Park Place, Suite 450
Annapolis, MD 21401
proxy
For The
Annual Meeting To Be Held June 13, 2008
The undersigned hereby constitutes and appoints John
Pappajohn and David P. Wright, and each of them, attorneys and agents, with
full power of substitution, to vote as proxy all 8% Convertible Notes issued August 3,
2007 of PharmAthene, Inc.(the “Company”)
standing in the name of the undersigned at the Annual Meeting of Stockholders
of the Company to be held at the offices of The Bear Stearns Companies, Inc.
located at 383 Madison Avenue, New York, New York 10179 at 10:00 a.m., New
York time, on Friday, June 13, 2008, and at any adjournment or
postponement thereof, in accordance with the instructions noted below, and with
discretionary authority with respect to such other matters as may properly come
before such meeting or any adjournment or postponement thereof. Receipt of
notice of such meeting and the Proxy Statement therefor dated May ,
2008 is hereby acknowledged.
This Proxy will be voted in accordance with the Noteholder’s
specifications hereon. In the absence of any such specification, this Proxy
will be voted:
·
“FOR” James H. Cavanaugh, Ph.D., Elizabeth Czerepak
and Steven St. Peter as Directors of the Company.
The undersigned hereby revokes any
proxies heretofore given and directs said attorneys to act or vote as follows:
1. Election
of directors:
01 James H. Cavanaugh, Ph.D.
03 Steven St. Peter
02 Elizabeth Czerepak
o
Vote FOR all nominees listed (except as marked)
o
Vote WITHHOLD AUTHORITY to vote for all nominees
listed
FOR all nominees listed, except that authority to
vote withheld for the following nominee(s): Write the number(s) of the
nominee(s) in the box provided to the right.
THIS PROXY IS SOLICITED ON BEHALF OF THE HOLDERS OF
THE COMPANY’S 8% CONVERTIBLE NOTES ISSUED AUGUST 3, 2007
SIGN HERE EXACTLY AS NAME(S) APPEAR(S) ON THE CARD
Date
Signature(s)
NOTE: When shares are held by joint tenants, both should sign. When
signing as attorney, trustee, administrator, executor, guardian, etc., please
indicate your full title as such. If a corporation, please sign in full
corporate name by President or other authorized officer. If a partnership,
please sign in full partnership name by authorized person.
Please complete
and date this proxy and return it promptly
in the
enclosed postage-prepaid envelope.
PharmAthene, Inc.
One Park Place, Suite 450
Annapolis, Maryland 21401
May 5, 2008
VIA EDGAR
United States Securities and Exchange Commission
Office of Emerging Growth Companies
100 F Street, NE - Mail Stop 6010
Washington, D.C. 20549
Attn: Mr. Jeffrey
Reidler
Ms. Sonia Barros
Re:
PharmAthene, Inc.
Preliminary Proxy Statement
Filed on April 29, 2008
File No. 1-32587
Dear Sir and Madam:
Pursuant to the letter from the Staff, dated May 2, 2008,
PharmAthene, Inc. (the “Company”) acknowledges that:
· the Company is
responsible for the adequacy and accuracy of the disclosure in the filing;
· Staff comments or
changes to disclosure in response to staff comments do not foreclose the
Commission from taking any action with. respect to the filing; and
· the Company may
not assert Staff comments as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United
States.
In addition, we understand and acknowledgement that that the Division
of Enforcement has access to all information which we have provided to the
Staff of the Division of Corporation Finance in its review of our filing or in
response to SEC comments on our filing.
Sincerely,
PharmAthene, Inc.
By:
/s/David P. Wright
David P. Wright
President and Chief Executive Officer